NewsLargest Real-World Study Of Immunotherapy Shows Men With Advanced Prostate Cancer With Low PSA Had A Median Survival Of Nearly Four Years After Treatment With PROVENGE® (Sipuleucel-T)
Largest Real-World Study Of Immunotherapy Shows Men With Advanced Prostate Cancer With Low PSA Had A Median Survival Of Nearly Four Years After Treatment With PROVENGE® (Sipuleucel-T)